OptimizeRx Corporation
OPRX
$16.96
-$0.29-1.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.19% | 11.37% | 13.91% | 30.48% | 36.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.19% | 11.37% | 13.91% | 30.48% | 36.14% |
| Cost of Revenue | 48.56% | 14.67% | -2.23% | 20.38% | 18.61% |
| Gross Profit | 59.22% | 9.34% | 23.44% | 37.21% | 49.57% |
| SG&A Expenses | -0.06% | -11.15% | 18.57% | 4.18% | 17.78% |
| Depreciation & Amortization | 0.09% | 2.53% | 8.64% | 134.48% | 130.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.27% | -2.74% | 9.80% | 12.56% | 20.86% |
| Operating Income | 185.06% | 57.96% | 61.65% | 69.80% | 22.69% |
| Income Before Tax | 133.61% | 49.90% | 118.81% | -246.98% | -23.45% |
| Income Tax Expenses | 116.64% | -415.41% | 130.09% | -- | -3,396.97% |
| Earnings from Continuing Operations | 138.22% | 68.13% | 98.12% | -218.46% | 3.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 138.22% | 68.13% | 98.12% | -218.46% | 3.68% |
| EBIT | 185.06% | 57.96% | 61.65% | 69.80% | 22.69% |
| EBITDA | 247.08% | 71.28% | 48.48% | 95.81% | 36.97% |
| EPS Basic | 137.72% | 68.63% | 98.20% | -189.14% | 10.37% |
| Normalized Basic EPS | 133.14% | 50.73% | 51.01% | 22.30% | -14.89% |
| EPS Diluted | 136.36% | 68.42% | 98.26% | -190.36% | 10.17% |
| Normalized Diluted EPS | 132.28% | 50.73% | 51.01% | 22.30% | -14.89% |
| Average Basic Shares Outstanding | 1.39% | 1.65% | 3.61% | 10.13% | 7.45% |
| Average Diluted Shares Outstanding | 4.15% | 1.65% | 3.61% | 10.13% | 7.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |